Vistagen
NEWS
Developing treatments to help those struggling with depression, a disorder that can lead to suicide, has become a mission for Shawn Singh, CEO of VistaGen, and his colleagues.
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing better and alternative treatments for depression.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
JOBS
IN THE PRESS